Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Abstract Background The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Becky A. S. Bibby, Niluja Thiruthaneeswaran, Lingjian Yang, Ronnie R. Pereira, Elisabet More, Darragh G. McArt, Paul O’Reilly, Robert G. Bristow, Kaye J. Williams, Ananya Choudhury, Catharine M. L. West
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2021-07-01
Edice:	BMC Urology
On-line přístup:	https://doi.org/10.1186/s12894-021-00856-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!